Glaucoma is a prevalent neurodegenerative disorder of the eye. However, the mechanism leading to the disease is still unclear. Increased intraocular pressure (lOP) and subsequent retinal ganglion cell (RGC) death leading to the loss of visual field characterizes the pathology of primary open angle glaucoma, which is the most common form. Possible factors leading to glaucoma include glutamateinduced neurotoxicity, nitric oxide (NO) based damage, disruption of neurotrophic factor transport and immune-induced neurodestruction. Current treatment options primarily aim at decreasing lOP by utilizing pharmacological agents, laser therapy and surgery. Developing treatments target neuroprotection with vaccines, the inhibition of NO synthesis and apoptosis. Gaining a better understanding of the pathogenesis can aid in the development of new treatment options and, perhaps, even a cure for glaucoma.
Glaucoma is characterized by the slow, progressive degeneration of retinal ganglion cells (RGCs) and optic nerve axons. The disease affects over 66 million people worldwide, causing bilateral blindness in 6.8 million (1) . The most common form of the disease is primary open angle glaucoma (POAG), with a prevalence ranging from 0.58% in Asian Americans and as high as 6.7% in African Americans (2) . African-Americans have a greater prevalence of the disease, contributed by optic nerve damage occurring at an earlier age, incurring more severe damage than other ethnic groups and experiencing less surgical repair successes. There are several recognized risk factors for glaucoma, such as an increased intraocular pressure (lOP), aging, family history, high myopia, systemic hypertension, cardiovascular disease, migraine headaches, peripheral vasospasm and prior nerve damage (1, (3) (4) . The visual damage incurred from glaucoma is considered irreversible. However, it can be treated if diagnosed at an early enough stage. Since blindness is ultimately induced by the loss of visual field caused by neuronal cell death, understanding the pathology that leads to increased lOP, and subsequently to neuronal cell death, is crucial to the development of effective treatments. of the "classical triad": characteristic pattern of visual field defects, morphological loss of optic disk substance and increased lOP (2) . Central visual acuity is relatively resistant to glaucomatous damage in the initial stages of the disease, with the peripheral vision mainly affected. Selective perimetry and visual field testing can effectively identify changes to the peripheral field. Examination of the optic disk is perhaps the most valuable method in early diagnosis, characterized by a concomitant decrease in the width of the neuroretinal rim and enlargement of the optic disc cup (I). Increased lOP of greater than 21 mm Hg (mean adult of 15-16 mm Hg) is not required for diagnosis, though it has traditionally been suspected to cause glaucoma (5) . Patients with POAG typically exhibit increased resistance to the outflow of aqueous humor through the trabecular meshwork, which can result in an increase in lOP and subsequent cell death from compression of the optic nerve axons (I).
Genetically, no single Mendelian mode of inheritance can describe POAG (I). Rather, it seems to be determined by the interactions of multiple genes which may either increase or decrease the risk of glaucoma. In contrast, other forms of glaucoma, including congenital glaucoma and Reiger syndrome, can be mapped to specific genes leading to deformation ofthe anterior chamber ofthe eye (6) . Recently, genomic mutations that are associated with POAG have been identified; one example is myocilin (MYOC), which may be responsible for 2-4% of POAG in the world (6) . The mutation exhibits an autosomal dominant pattern of inheritance. MYOC itself is expressed in the human trabecular meshwork and several other ocular tissues, though its cellular function is still unknown (6)
DEVELOPING CONCEPTS OF PATHOLOGY Neurotoxicity
Glutamate Excitotoxicity Activation of glutamate receptors may contribute to cellular apoptosis and neuronal cell death. In glaucoma, there is a chronic elevation of glutamate concentrations in the inner eye (7) . Glutamate receptors are either metabotrophic (mGluR) or ionotropic (8) .
The effects of mGluRs have been less characterized in glaucoma, but studies suggest a relationship between increased lOP and mGluR (8) (9) . There is a significant increase in the expression of several mGluR subunits, in glaucomatous mice when compared to the control mice (8) . However, it is unknown if these observed changes in mGluR contribute directly to cellular apoptosis or occur as a result of apoptosis (8) .
Neurotoxicity resulting from ionotropic receptors has been better characterized. In glaucoma, it is thought that activation of both NMDA and non-NMDA ionotropic receptors increases intracellular calcium, stimulating a variety of intracellular enzymes, which ultimately leads to RGC death (10) . However, a recent study suggests RGCs are in fact invulnerable to glutamate excitotoxicity; the RGC layer has equal numbers of RGCs and displaced amacrine cells, suggesting that past experiments may have misinterpreted cell death in the RGC layer without proper distinction between RGCs and amacrine cells (7) . Past studies may also have only observed cell death in prolonged exposures (>24 hours), where cell death of RGCs is observable. However, this may be due to trophic deprivation from loss of amacrine signals, rather than delayed excitotoxicity (7) .
NO Neurotoxicity
NO is known as a second messenger, important in the relaxation of smooth muscle. Excess NO is associated with stroke, Parkinson's disease, Alzheimer's disease and multiple sclerosis (11). Nitric oxide synthase-2 (iNOS-2) is an inducible form of NOS that is not normally present in tissue, but it makes an excessive quantity of NO when present (12) . In glaucoma, intense labeling of iNOS-2 in reactive astrocytes of severely damaged regions was observed. Stimulation of the human lamina cribrosa astrocyte culture with cytokines results in intense labeling of iNOS-2, with subsequent excess NO production inducing neurotoxicity (13) .
Disrupted transport ofneurotrophic factors
Neurotrophins, or neurotrophic factors (NTFs), are polypeptides that regulate the growth, differentiation and death ofneurons. They originate from the superior calliculus of the central nervous system (CNS), and their transport may be disrupted by high lOP (14) . NTFs can also be made locally in the retina, lamina cribosa or optic nerve body, and act in an autocrine or paracrine fashion (15) . The lack ofNTFs has been suggested to be a factor that causes RGC apoptosis. These factors bind and phosphorylate Trk receptors, resulting in an anti-apoptotic effect. The expression of Trk receptor families (TrkA, Band C) also partially regulates p75 receptors, which induce apoptosis when activated (14) .
Under high lOP, transient expression of TrkA receptors and truncated TrkC receptors in the glial cells have been observed (14) . Transient expression of TrkA receptors may not provide sufficient neurotrophic support, and ineffective truncated TrkC receptors could competitively inhibit the TrkC receptor, which further decreases the available neurotrophins to the RGC since NTFs act in an autocrine or paracrine fashion locally. Furthermore, since p75 receptors are partially controlled by Trk receptors, truncated TrkC receptors may contribute to p75 activation. Under increased lOP, p75 was upregulated (14) .
Neurinflammation
Long term presence of lymphocytes and antigens from sustained neurodegeneration can lead to increased T-cells. Cytokines are subsequently released, resulting in secondary antigen-mediated neurotoxicity similar to that in autoimmune diseases. A 67% increase in cytokine receptors has been detected in normal pressure glaucoma (NPG) patients, and a 77% increase in POAG patients, suggesting T-cell over-activation in glaucomatous patients (16) .
In support of autoimmune neuropathy in NPG, there has been an epidemiological association of immune-related disease with 30% of NPG patients, versus 8% of control patients (16) . Autoantigens in NPG are similar to those found in autoimmune thyroid disease, rheumatoid arthritis and type 1 diabetes (17) . This may provide the link to the increased association of diabetes and glaucoma. An example of molecular mimicry that has been suggested as a pathogenic factor in glaucoma is the antibodies for heat shock proteins (hsps) (17) . Hsps assist in protein folding and assembly, and are initially helpful by responding to stressors increased lOP. However, they become harmful when they persist and can induce neuronal apoptosis (18) .
Glaucoma-stressed neurons can also lead to cell death via immune response surveillance. Cell death occurs by the activation of a protease called caspase, which depletes the cell of energy sources, NAD and ATP, eventually cleaving and unraveling DNA. Ischemia and the excessive production of hsp antibodies have been found to activate caspase (19) . Thus, sustained optic neuropathy can result from normal immune surveillance repairing infected neuronal cells ( Fig. 1) .
Neuroprotection T-cells can protect neurons from axonal injury by destroying damaged cells and removing pathogenic agents, referred to as protective immunity (18) . When splenocytes from rats with neurons resistant to damage caused by lOP were transferred to rats with susceptible neurons, the susceptible rats became resistant to damage caused by high lOP (20) . This suggests that the susceptibility of neuronal damage to high lOP is immune-dependent.
Some degree of T-cell activity may be necessary for the survival of neurons at an increased lOP state. A recent study investigated whether methylprednisolone can eliminate T-cell induced inflammation due to CNS insult, resulting in the destruction of neurons (21) . Researchers injected methylprednisolone to glaucomatous rat eyes and found that not only did it fail to protect RGC from inflammation-induced death, but it also caused RGC death, suggesting the presence of T-cells might be necessary for neuroprotection (21) .
CURRENT TREATMENT OPTIONS
The goal of treating glaucoma lies primarily on preventing or delaying the loss of visual field (13) . Since neuronal cell death is irreversible, no cure is available once the visual field is lost. However, since lOP is the primary risk factor causing the loss of RGCs, the strategies of treatment mostly involve lowering lOP (13) . Other important factors such as cost, convenience and safety should also be considered (22) . Current treatments for glaucoma include medication, laser use and surgery.
Medications
Medications involve inhibiting the inflow of aqueous humor, enhancing the outflow of aqueous humor, protecting the optic nerves (23) and manipulating the osmotic pressure between plasma and the eyes (5) .
u2 adrenoreceptor agonists and~1 receptor antagonists lower lOP by inhibiting the inflow of aqueous humor to the eye. Timolol, which is the most prescribed drug, and betaxolol, which has the fewest systemic side effects, are both~l receptor blockers (23) . A third type of drug that inhibits the inflow of humor is carbonic anhydrase inhibitors, such as acetazolamide and dorzolamide. Such drugs are often formulated together as in Cosopt (dorzolamide hydrochloride and timolol maleate) (22) .
Another method of reducing lOP is by enhancing the outflow ofhumor from the eyes through the use of muscarinic acetylcholine receptor agonists (23) (24) . This mechanism is indirect, but involves a muscarinic acetylcholine receptor (M3)-mediated contraction of the ciliary muscle (23) . The contraction causes the widening of the spaces in the trabecular meshwork. The newest class of drugs using this strategy is the prostaglandin F2u derivatives which enhance the uveoscleral outflow (25) . Bimatoprost falls under this category and is considered the most effective anti-glaucoma drug (23) .
Laser and Surgery
A secondary choice of treatment of glaucoma is the use of laser therapy. The primary strategy involves "burning" holes in various areas within the eyes including the ciliary and the pigmented trabecular meshwork cells (24) . The benefits include being noninvasive, needing less patient compliance and lowering the possibility of infection or bleeding. The lOP of most patients can decrease about 20-30%, but the treatment effect wears off 5-10% every year. In combination with timolol, the two year lOP lowering success rate is 70%, compared with the laser alone (44%) and timolol alone (30%) (24) .
A common form of surgery is trabeculectomy, which creates a guarded channel allowing aqueous humor to flow from the anterior chamber inside the eye to sub-Tenon's and subconjunctival space (24) (25) . The benefits of surgery include stabilizing lOP and bypassing the requirements for strict patient compliance and continuous drug costs (24) . Surgery is considered as the last resort because failure of surgery can result in immediate blindness due to complications such as choroidal effusion, hypotonic maculopathy, suprachoroidal hemorrhage and optic nerve snuffing (24) .
FUTURE TREATMENT OPTIONS
Based on new knowledge gained from research on the pathology of neuronal apoptosis, there are several forms of new treatments. Many of these treatments focus on neuroprotection through antiapoptosis of RGCs.
Neuroprotective Vaccines
Since resistance to high lOP is immunedependent, T-cell induced neuroprotection may vaccinate the RGC from apoptosis. For example, copolymer-l may be used as a vaccine because it is an antigen that cross-reacts with a wide range of Tcells, and can provoke a protective immune response to protect RGC from cell death caused by toxins or increased IOP (21) .
A crucial consideration for designing neuroprotective vaccines is the site of protection. Some have suggested that the target should be in the RGC and not in the optic nerves because during the early glaucomatous stage cell death induced by increased lOP occurs in the RGC, not in the optic nerve (21) . R 16, a peptide derived from the RGC, is one example of a neuroprotective vaccine. Although R16 can cause slight RGC death for those without glaucoma, the benefit from this treatment far exceeded the damage from untreated glaucoma conditions (21) .
NMDA Receptor Antagonists
Memantine is a NMDA receptor antagonist that blocks excessive NMDA receptor activity. This drug has been approved for clinical use in Europe for the treatmentofAlzheimer's diseaseand vasculardementia, though its effectiveness in preventing glaucomatous RCG degeneration is stil; unknown (26) .
iNOS-2 Inhibitors
Since the upregulation of iNOS-2 is harmful to neurons, its inhibition might have a neuroprotective effect. An inhibitor such as aminoguanidine can prevent the death of about 75% of RGCs during 6 months of induced elevated lOP and prevent further loss ofRGC (12) .
Although an unregulated level of NO can cause neuronal degeneration via apoptosis, a small amount of NO could inhibit apoptosis. Survival of serum deprived peochromocytoma PC-12 cells was observed when treated with S-nitroso-Nacetylpenicillamine (Nipradilol), which is an NO donor (27) . Nipradilol is unique because it can decrease both lOP and protect neurons by releasing a small amount of NO.
Nutritional Supplements
An interesting alternative to aminoguanidine is Ginkgo biloba extract (EGb 761). Ginkgo biloba is used as a nutritional supplement for the reduction of platelet aggregation, vasodilation and reduction of blood viscosity (28) . EGb 761 contains 24% flavonoid glycosides and 6% terpenoids, which may inhibit toxicity and NO free radical accumulation by inhibiting iNOS (29) . In experiments when lOP is elevated in rats by cautery of episcleral vessels, feeding the rats 30 mg ofEGb 761 per day for 5 months decreased RGC loss from 29.9% to 4.6% (n=5) (29) . Further investigation monitoring the modulation of NO in response to EGb 761 treatment could provide insight into its neuroprotective mechanism.
In human models, EGb 761 was able to significantly improve the visual field indices in patients with NPG and pre-existing visual field damage (30) . However, a discontinuation of EGb 761 resulted in a reversion of visual field indices, suggesting that EGb 761 may require continuous administration (28) . While EGb 761 may be appealing because it is a nutritional supplement and not a prescription drug, care should be taken because the effects of EGb 761 are not fully understood and there have been some reports of toxicity.
Calcium Channel Blockers
Most apoptotic mechanisms involve nsmg intracellular calcium levels. Flunarizine, a calcium channel blocker, has been shown to significantly enhance RGC survival in rat and rabbit models by reducing lOP ((31-32) . However, the exact mechanism of this and other calcium channel blockers needs to be elucidated.
STAT-3 Activation
Another target is the signal transducers and activators of transcription protein-3 (STAT-3). They play an importantrole in cell growth and differentiation and are of interest because the mRNA of this protein is upregulated in rats with glaucoma (33) .
The activation of STAT-3 pathway might inhibit apoptosis by suppressing caspase-3. One molecule that has been investigated is ciliary neurotrophic factor (CNTF), which is an interleukin-6 cytokine. Fig. 1 . Potential roles ofthe immune system in facilitating glaucomatous damage (19) . 
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Caspase-3 inhibitor Q Geranylgeranylacetone Hsps mediation Erythropoietin PI-3kinase/Akt pathway The injection of CNTF into rat eyes with increased lOP reduces apoptosis, phosphorylates STAT-3, and reduces the activity of caspase-3 (34) . Interleukin-l 0 also has neuroprotective activity through the STAT-3 pathway (35) .
Caspase Inhibitors
Inhibitors of apoptosis protein (lAP) can also reduce apoptosis by inhibiting caspase. Baculoviral lAP repeat-containing protein-4 (BIRC-4) is a direct inhibitor of caspase 3, 7 and 9. BIRC-4, transducted into the eye, can inhibit apoptosis of optic nerve axons (36) .
A pharmacological approach for apoptosis inhibition is the use of minocycline, which can inhibit caspase-3-induced apoptosis (37) .
It increases the survival rate of RGC exposed to the harmful effects of glutamate. Furthermore, it can function synergistically with MK-80I, an antagonist to NMDA receptors, to increase RGC survival rate.
Heat Shock Proteins
Geranylgeranylacetone (GGA) is an acyclic polyisoprenoid currently used in Japan as an antiulcer drug. The neuroprotective effects of the drug are facilitated through the use of hsps. In particular, HSP72 seems to act as an anti-apoptotic chaperone protein that interferes with multiple stages in the apoptotic pathway. Mechanistically, the drug is believed to activate Heat Shock Factor 1 (HSF-1), a transcription factor for hsps, which oligomerizes in the cytosol and translocates into the nucleus when exposed to stressors (38) .
Erythropoietin
Erythropoietin (EPO) is a hematopoietic factor that stimulates differentiation and proliferation of erythroid progenitor cells. It is also neuroprotective and may prevent further RGC death by inhibiting apoptosis (39) . EPO receptors are found on cell bodies and dendrites of RGCs. Intravitreal injection of EPO in rats with axotomized RGCs enhances RGC survival by 92% compared to those without EPO injection. However, RGC survival rate is dependent on the dosage. Dosage less than 4 ul of O.lM EPO decreases its efficiency, but does not have the toxic effects of higher doses (39) .
The suggested mechanism of neuroprotection is by the PI-3kinase/Akt pathway, which inhibits apoptosis by maintaining mitochondrial membrane potential, preventing cytochrome c release, and consequently inhibiting caspase (40) . A membrane potential indicator shows that the addition of EPO maintains the function of RGCs by decreasing depolarization caused by anoxia or excessive NO. In addition, EPO reduces caspase activity, indicated by a decrease in the absorbance of colorimetric caspase substrates (40) .
While axotomy, neurotrophic deprivation and increased NO mimic the conditions of glaucoma, it is important to note that lOP was not increased in these experiments, and thus the application to glaucoma treatment is not perfect. The injection of EOP does not regenerate RGCs, but it can prevent neuronal injury. EPO decreases DNA fragmentation caused by anoxia or NO, indicated by terminal deoxynucleotidyl transferase nick end labeling. Care should also be taken to ensure that erythrocytes from EOP injection do not aggregate in the retina and cause occlusion (40) .
CONCLUSION
Glaucoma is a common neurodegenerative disorder characterized by loss of RGCs, ultimately leading to reduction of the visual field and potential blindness. New and emerging research has provided a number of insights about the pathology, identifying new underlying factors including glutamate excitotoxicity, NO neurotoxicity, disruption of neurotrophic factor transport and aberrant autoimmune responses. As a result, novel targets for treatment are now in development with the primary objective of neuroprotection through anti-apoptotic mechanisms. Examples include neuroprotective vaccines, NMDA receptor antagonists, calcium channel blockers, NOS-2 inhibitors, erythropoietin and a number of drugs and supplements that inhibit the caspase pathway. It is, however, important to note that these factors are not independent of each other. Treatment interactions and their effects on other tissues should also be researched, especially since results from various experiments seem contradictory. For example, excess NO causes neuronal death, but less might inhibit apoptosis. Aberrant immune responses may lead to neuronal damage, but their absence might also promote neuronal death. While all current research is geared towards treatment options, the possibility of RGC regeneration should be explored to search for a glaucoma cure.
